摘要
目的观察吉西他滨(Gemcitabine,GEM)联合卡培他滨(Capecitabine,CAP)治疗蒽环类和紫杉类药物耐药的转移性乳腺癌(anthracycline-and taxane-refractory metastatic breast cancer,ATRMBC)患者的疗效和不良反应。方法37例ATRMBC患者,采用吉西他滨联合卡培他滨方案化疗:吉西他滨1000mg/m2静脉滴注,第1、8天;卡培他滨1000mg/m2口服,每日两次,第1～14天;每3周为1周期。结果37例患者共完成155周期化疗,中位化疗周期数为4周期。完全缓解1例(2.7%),部分缓解14例(37.9%),稳定13例(35.1%),进展9例(24.3%);客观有效率40.6%(95%CI24.8～56.4);临床获益率64.9%(95%CI:49.5～80.3);平均随访14.8月,中位疾病进展时间7.3月(95%CI6.2～8.4),中位生存期15.6月(95%CI12.6～18.6)。结论吉西他滨联合卡培他滨是治疗蒽环类和紫杉类药物耐药的转移性乳腺癌的有效方案,其血液学和非血液学毒性能够耐受。
Objective To evaluate the clinical efficacy and tolerability of gemcitabine combined with capecitabine for patients with anthracycline- and taxane-refractory metastatic breast cancer （ATRMBC）. Methods Thirty-seven ATRMBC patients were given intravenous gemcitabine 1 000 mg/m2 on the day 1 and 8, and oral capecitabine 1 000 mg/m2twice daily on the day 1~14 every 3 weeks. Results Thirtyseven patients completed 155 cycles of chemotherapy with a median number of 4 cycles per patient. One patient （2. 7%） achieved a complete response, and 14 patients （37. 9%） had a partial response, with an overall objective response rate of 40. 6%（95% confidence interval.. 24. 8 % ~ 56. 4% ）. Stable disease was documented in 13 patients （35. 1% while progressive disease occurred in 9 patients （24. 3%）. After average follow-up of 14. 8 months, the median time to progression was 7. 3 months （95% confidence interval： 6. 2~8.4 months）, and median overall survival time was 15.6 months （95% confidence interval： 12. 6~ 18. 6 months）. Conclusion The triweekly combined chemotherapy of gemcitabine with capecitabine is effective for ATRMBC patients. The hematologic and non-hematologic toxicities are well-tolera- ted.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2010年第1期88-90,共3页
Cancer Research on Prevention and Treatment
